Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
Retrieved on:
Thursday, November 10, 2022
Ecosystem, Review, Genomics, Genetic testing, Forward-looking statement, Exchange, International Financial Reporting Standards, HSBC, Knowledge, Colorectal cancer, Adjusted gross income, COVID-19 testing, Depreciation, COVID-19, Securities Act of 1933, Holocene, Mission statement, SEC, COVID, NASDAQ, Environmental impact of pharmaceuticals and personal care products, U.S. Securities and Exchange Commission, International, EBITDA, Company, Reconciliation (accounting), Patient, Growth, CEO, Table, Qatar Financial Information Unit, Industry, Diagnosis, Securities Exchange Act of 1934, Tutoring, Bookkeeping, Audit, Security (finance), Operation, Adjustment
Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.
Key Points:
- Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.
- For full year 2022, Prenetics raises revenue guidance to the range of US$270 million to US$280 million and raises full year adjusted EBITDA guidance to the range of US$47 million to US$53 million.
- Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release.
- An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."